Pharma BD Deal Intelligence
Servier Pharmaceuticals LLC / Black Diamond Therapeutics, Inc.
2025 · Licensing/Option · $780M · Complete
Black Diamond Therapeutics granted Servier Pharmaceuticals a worldwide license to develop and commercialize BDTX-4933, a small molecule designed to address RAF/RAS-mutant solid tumors. Servier leads development activities and worldwide commercialization across multiple indications including non-small cell lung cancer. Black Diamond receives a $70.0 million upfront payment and is eligible for up to $710.0 million in additional payments.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Mar 19, 2025
- Deal value $780M
- Deal type Licensing/Option
- Therapeutic area Oncology
- Indications RAF/RAS-mutant solid tumors, non-small cell lung cancer
- Key assets BDTX-4933 worldwide development and commercialization rights
- Mechanism Pan-RAF inhibitor
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Servier Pharmaceuticals LLC deals · Oncology deals